Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy.
Pediatr Pulmonol. 2023 Dec;58(12):3626-3629. doi: 10.1002/ppul.26673. Epub 2023 Sep 26.
Pediatr Pulmonol. 2023.
PMID: 37750598
No abstract available.
Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
Terlizzi V, Colangelo C, Marsicovetere G, D'Andria M, Francalanci M, Innocenti D, Masi E, Avarello A, Taccetti G, Amato F, Comegna M, Castaldo G, Salvatore D.
Terlizzi V, et al. Among authors: avarello a.
Genes (Basel). 2021 Jul 29;12(8):1178. doi: 10.3390/genes12081178.
Genes (Basel). 2021.
PMID: 34440351
Free PMC article.
Item in Clipboard
Cite
Cite